Price$1.05+0.02 (+2.43%)
02:45 PM03:15 PM
News · 26 weeks63+25%
2026-04-192026-10-11
Mix3190d
- SEC Filings12(39%)
- Other10(32%)
- Insider7(23%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SiteCAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition of Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE Study") evaluating the use of ProSense® cryoablation in the local treatment of low-risk breast cancer.The ChoICE study's co-primary investigator, Nathalie Johnson, M.D., FACS, serves as Senior Medical Director of the htt
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Medical Receives Regulatory Approval to Market ProSense® in ChinaCAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received approval, as a Class III medical device, from China's National Medical Products Administration ("NMPA") for its ProSense® system and associated cryoprobes. The NMPA approval represents an important regulatory milestone for IceCure and enables ProSense®, IceCure's flagship cryoablation system, to be marketed in China in accordance with
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the NetherlandsAgreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologiesCAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of IceCure's Pr
- PRWest Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer CryoablationPatients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TNCAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study ("ChoICE Study") for ProSense® cryoablation in the l
- SECSEC Form EFFECT filed by IceCure Medical Ltd.EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form EFFECT filed by IceCure Medical Ltd.EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
- INSIDERVP, Sales for North America Good Shad was granted 131,483 units of Ordinary Shares, increasing direct ownership by 2,521% to 136,698 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERSEC Form 3 filed by new insider Salton David3 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERVP, BD & Global Marketing Tel-Tzure Tlalit Bussi was granted 101,483 units of Ordinary Shares, increasing direct ownership by 2,016% to 106,518 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERVP, Human Resources Dotan Merav Nir was granted 73,890 units of Ordinary Shares, increasing direct ownership by 3,244% to 76,168 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERSEC Form 4 filed by Director Chan Vincent Chun Hung4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERChief Financial Officer Peleg Meir was granted 181,483 units of Ordinary Shares, increasing direct ownership by 1,361% to 194,816 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERChief Operating Officer Levav Shay was granted 141,483 units of Ordinary Shares, increasing direct ownership by 2,935% to 146,303 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- SECSEC Form S-8 filed by IceCure Medical Ltd.S-8 - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form POS AM filed by IceCure Medical Ltd.POS AM - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form POS AM filed by IceCure Medical Ltd.POS AM - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-EscalationNew review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastasesCAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-YearThe Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash positionCAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026. "We believe IceCure has reached an important inflec
ICCM FAQ
6 questionsWhat does IceCure Medical Ltd. do?
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.Where does ICCM stock trade?
IceCure Medical Ltd. (ICCM) is listed on NASDAQ.What sector and industry is ICCM in?
IceCure Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ICCM?
IceCure Medical Ltd. has had 2 recent analyst actions on file. The most recent action was from Brookline Capital: Buy with a $565.00 price target on 2022-02-02. Recent price targets range from $565.00 to $1450.00.What companies are similar to ICCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ICCM side-by-side with any of them on Quantisnow.How can I track ICCM on Quantisnow?
Quantisnow aggregates IceCure Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICCM to receive live email and push alerts on every new disclosure.